127 related articles for article (PubMed ID: 26332597)
1. Implementation of AMNOG: An industry perspective.
Leverkus F; Chuang-Stein C
Biom J; 2016 Jan; 58(1):76-88. PubMed ID: 26332597
[TBL] [Abstract][Full Text] [Related]
2. [Requirements for drug approval and additional benefits assessment: Regulatory aspects and experiences].
Broich K; Löbker W; Schulte A; Beinlich P; Müller T
Nervenarzt; 2016 Apr; 87(4):376-85. PubMed ID: 27003322
[TBL] [Abstract][Full Text] [Related]
3. Early benefit assessment of new drugs in Germany - results from 2011 to 2012.
Hörn H; Nink K; McGauran N; Wieseler B
Health Policy; 2014 Jun; 116(2-3):147-53. PubMed ID: 24472328
[TBL] [Abstract][Full Text] [Related]
4. [Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?].
Radic D; Haugk S; Radic M
Gesundheitswesen; 2018 Jun; 80(6):573-579. PubMed ID: 27636366
[TBL] [Abstract][Full Text] [Related]
5. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
Henschke C; Sundmacher L; Busse R
Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal products.
Schwander B; Banz K; Kaier K; Walzer S
Health Policy; 2014 Sep; 117(3):334-44. PubMed ID: 25059744
[TBL] [Abstract][Full Text] [Related]
7. [The AMNOG and its consequences].
Dingermann T
Internist (Berl); 2013 Jun; 54(6):769-74. PubMed ID: 23475259
[TBL] [Abstract][Full Text] [Related]
8. Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs.
Skipka G; Wieseler B; Kaiser T; Thomas S; Bender R; Windeler J; Lange S
Biom J; 2016 Jan; 58(1):43-58. PubMed ID: 26134089
[TBL] [Abstract][Full Text] [Related]
9. [Actual medical care situation and therapeutic needs in multiple sclerosis: Impact of the Pharmaceutical Market Restructuring Act (AMNOG)].
Bittner S; Meuth SG
Nervenarzt; 2016 Apr; 87(4):394-401. PubMed ID: 27023842
[TBL] [Abstract][Full Text] [Related]
10. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
11. [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences].
Kvitkina T; ten Haaf A; Reken S; McGauran N; Wieseler B
Z Evid Fortbild Qual Gesundhwes; 2014; 108(8-9):528-38. PubMed ID: 25523852
[TBL] [Abstract][Full Text] [Related]
12. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
Fischer KE; Stargardt T
Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
[TBL] [Abstract][Full Text] [Related]
13. [The new German drug market law AMNOG from a child and adolescent psychiatry perspective].
Dittmann RW
Nervenarzt; 2016 Apr; 87(4):367-75. PubMed ID: 26992908
[TBL] [Abstract][Full Text] [Related]
14. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
15. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
Ruof J; Schwartz FW; Schulenburg JM; Dintsios CM
Eur J Health Econ; 2014 Jul; 15(6):577-89. PubMed ID: 23771769
[TBL] [Abstract][Full Text] [Related]
16. [Drug assessment: IQWiG, G-BA, and an international comparison].
Glaeske G
Internist (Berl); 2016 Jan; 57(1):94-101. PubMed ID: 26502888
[TBL] [Abstract][Full Text] [Related]
17. "Market withdrawals" of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations.
Staab TR; Walter M; Mariotti Nesurini S; Dintsios CM; Graf von der Schulenburg JM; Amelung VE; Ruof J
Health Econ Rev; 2018 Sep; 8(1):23. PubMed ID: 30229501
[TBL] [Abstract][Full Text] [Related]
18. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
19. Regulatory reforms and GCP clinical trials with new drugs in India.
Maggon K
Clin Trials; 2004; 1(5):461-7. PubMed ID: 16279284
[TBL] [Abstract][Full Text] [Related]
20. [Quantifying the additional clinical benefit of new medicines: little - considerable - significant - 6 remarks from a biometrician's point of view].
Vach W
Gesundheitswesen; 2014 Nov; 76(11):757-62. PubMed ID: 24554518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
